#2122450
Na meastacháin i leith an ghéarnochta is airde, léiríonn siad géarnochtadh atá gar don ghéardháileog thagartha.
The highest acute exposure estimates indicate an acute exposure close to the acute reference dose.
Na meastacháin i leith an ghéarnochta is airde, léiríonn siad géarnochtadh atá gar don ghéardháileog thagartha.
The highest acute exposure estimates indicate an acute exposure close to the acute reference dose.
géardháileog thagartha (ARfD) a leagan síos, i gcás inarb ábhartha, do dhaoine;
establish, where relevant, an acute reference dose (ARfD) for humans;
Beidh san áireamh sna sainchomhaid a thíolactar de bhun Airteagal 7(1) an fhaisnéis is gá chun an Iontógáil Laethúil Inghlactha (ADI), Leibhéal Inghlactha i dtaca leis an Oibreoir a bheith faoi lé na Substainte (AOEL) agus an Ghéardháileog Thagartha (ARfD) a shuíomh más ábhartha.
The dossiers submitted pursuant to Article 7(1) shall contain the information needed to establish, where relevant, Acceptable Daily Intake (ADI), Acceptable Operator Exposure Level (AOEL) and Acute Reference Dose (ARfD).
Thairis sin, tháinig an tÚdarás ar an gconclúid nach bhfuil gá le géardháileog thagartha a bhunú mar gheall ar phróifíl ghéarthocsaineachta íseal na substainte.
Moreover, the Authority concluded that the establishment of an acute reference dose is not necessary due to the low acute toxicity profile of the substance.
Bhunaigh sé géardháileog thagartha ghrúpa ina bhfuil 1 μg/kg de mheáchan coirp (b.w.) agus iontógáil laethúil infhulaingthe ghrúpa ina bhfuil 0,6 μg/kg b.w. in aghaidh an lae.
It established a group acute reference dose of 1 μg/kg body weight (b.w.) and a group tolerable daily intake of 0,6 μg/kg b.w. per day.
Shocraigh an tÚdarás géardháileog thagartha ghrúpa (“ARfD”) arb é atá inti 0,016 μg/kg den mheáchan choirp (“b.w.”) arna sloinneadh mar shuim an (-)-hióisciaimín agus an (-)-scópolaimín, ag glacadh leis go bhfuil neart coibhéasach ann.
The Authority established a group acute reference dose (‘ARfD’) of 0.016 μg/kg per body weight (‘b.w.’) expressed as the sum of (-)-hyoscyamine and (-)-scopolamine, assuming equivalent potency.
Thairis sin, tháinig an tÚdarás ar an gconclúid nach bhfuil gá le géardháileog thagartha a bhunú ar bhonn phróifíl ghéarthocsaineachta íseal na substainte gníomhaí.
Moreover, the Authority concluded that the establishment of an acute reference dose is not necessary on the basis of the low acute toxicity profile of the active substance.
Thairis sin, tháinig an tÚdarás ar an gconclúid nach bhfuil gá le géardháileog thagartha a bhunú mar gheall ar phróifíl ghéarthocsaineachta íseal na substainte.
Moreover, the Authority concluded that the establishment of an acute reference dose is not necessary due to the low acute toxicity profile of the substance.
Thairis sin, tháinig an tÚdarás ar an gconclúid nach bhfuil gá le géardháileog thagartha a bhunú ar bhonn phróifíl ghéarthocsaineachta íseal na substainte gníomhaí.
Moreover, the Authority concluded that the establishment of an acute reference dose is not necessary on the basis of the low acute toxicity profile of the active substance.
Tháinig an tÚdarás ar an gconclúid nár cheart go mbeadh éifeachtaí díobhálacha géara ag nochtadh an duine faoi bhun na géardháileoige tagartha (ARfD) 20 μg ciainíd/kg meáchan coirp (bw).
The Authority concluded that a human exposure below the acute reference dose (ARfD) of 20 μg cyanide/kg body weight (bw) should not produce acute adverse effects.
Shocraigh an tÚdarás an ghéardháileog thagartha (ARfD) arb é atá inti 1 μg Δ9-THC/kg de mheáchan coirp (bw).
The Authority established an acute reference dose (ARfD) of 1 μg Δ9-THC/kg body weight (bw).
Mhol an tÚdarás, ar bhonn na staidéar ar néarthocsaineacht fhorbarthach, gur cheart iontógáil laethúil inghlactha níos ísle (ADI) agus géardháileog thagartha (ARfD) níos ísle a leagan síos.
The Authority proposed, based on the developmental neurotoxicity studies, that a lower acceptable daily intake (ADI) and acute reference dose (ARfD) should be established.
Thairis sin, tugadh le fios sa réamh-mheasúnú ar ghéar-riosca cothútháin i gcás tomhaltóirí gur sáraíodh go mór an ghéardháileog thagartha le haghaidh na n-úsáidí ionadaíocha uile maidir leis na barra inite uile.
Furthermore, the preliminary acute consumer dietary risk assessment indicated a large exceedance of the acute reference dose (‘ARfD‘) for all the representative uses on all edible crops.
(c) tá an iontógáil laethúil inghlactha a bhaineann léi, a géardháileog thagartha, nó a leibhéal inghlactha risíochta i gcás oibreoirí, de réir mar is iomchuí, níos ísle go mór ná an iontógáil laethúil inghlactha, an ghéardháileog thagartha nó an leibhéal inghlactha risíochta i gcás oibreoirí a bhaineann le formhór na substaintí gníomhacha maidir leis an gcineál céanna táirge agus maidir leis an gcás céanna úsáide;
(c) its acceptable daily intake, acute reference dose or acceptable operator exposure level, as appropriate, is significantly lower than those of the majority of approved active substances for the same product-type and use scenario;
Le teagmháil ar feadh an tsaoil le clórprófam trí chaitheamh na dtáirgí bia go léir a d’fhéadfadh é a bheith iontu, agus le nochtadh gearrthéarmach do chlórprófam agus a mhór-mheitibilít 3-clóranailín, trí go leor prátaí a chaitheamh, léiríodh nach bhfuil baol ann go sárófaí an iontógáil laethúil inghlactha nó an ghéardháileog thagartha.
Neither the lifetime exposure to chlorpropham via consumption of all food products that may contain it, nor the short-term exposure to chlorpropham and its major metabolite 3-chloroaniline, due to high consumption of potatoes, showed that there is a risk that the acceptable daily intake or the acute reference dose is exceeded.
Le teagmháil ar feadh an tsaoil leis na substaintí sin trí chaitheamh na dtáirgí bia go léir a bhféadfadh iad a bheith iontu, agus le teagmháil ghearrthéarmach i ngeall ar go leor de na táirgí ábhartha sin a chaitheamh, léiríodh nach bhfuil baol ann go sárófaí an iontógáil laethúil inghlactha nó an ghéardháileog thagartha.
Neither the lifetime exposure to these substances via consumption of all food products that may contain them, nor the short-term exposure due to high consumption of the relevant products showed that there is a risk that the acceptable daily intake or the acute reference dose is exceeded.
Le teagmháil ar feadh an tsaoil leis na substaintí seo trí chaitheamh na dtáirgí bia go léir a bhféadfadh siad a bheith iontu, agus le teagmháil ghearrthéarmach i ngeall ar go leor de na táirgí ábhartha sin a chaitheamh, léiríodh nach bhfuil baol ann go sárófaí an iontógáil laethúil inghlactha nó an ghéardháileog thagartha.
Neither the lifetime exposure to these substances via consumption of all food products that may contain them, nor the short-term exposure due to high consumption of the relevant products showed that there is a risk that the acceptable daily intake or the acute reference dose is exceeded.
Le teagmháil ar feadh an tsaoil agus le teagmháil ghearrthéarmach i ngeall ar go leor de na táirgí ábhartha sin a chaitheamh, léiríodh nach bhfuil baol ann go sárófaí an iontógáil laethúil inghlactha nó an ghéardháileog thagartha.
Neither the lifetime nor the short-term exposure due to high consumption of the relevant products showed that there is a risk that the acceptable daily intake or the acute reference dose is exceeded.
Le teagmháil ar feadh an tsaoil leis na substaintí seo trí chaitheamh na dtáirgí bia go léir a d’fhéadfadh iad a bheith iontu, agus le teagmháil ghearrthéarmach trí go leor de na táirgí ábhartha a chaitheamh, léiríodh nach bhfuil baol ann go sárófaí an iontógáil laethúil inghlactha nó an ghéardháileog thagartha.
Neither the lifetime exposure to these substances via consumption of all food products that may contain them, nor the short-term exposure due to high consumption of the relevant products showed that there is a risk that the acceptable daily intake or the acute reference dose is exceeded.
Léiríodh nach baol do dhuine an iontógáil laethúil inghlactha a shárú, ná an ghéardháileog thagartha a shárú, de bharr ceachtar den dá rud seo: teagmháil ar feadh a shaoil leis na substaintí sin, ná caitheamh na dtáirgí bia go léir bhféadfaidís a bheith iontu.
Neither the lifetime exposure to these substances via consumption of all food products that may contain them, nor the short-term exposure due to high consumption of the relevant products showed that there is a risk that the acceptable daily intake or the acute reference dose is exceeded.
Le teagmháil ar feadh an tsaoil leis na substaintí sin trí chaitheamh na dtáirgí bia go léir a d’fhéadfadh iad a bheith iontu, agus le teagmháil ghearrthéarmach trí go leor de na táirgí ábhartha a chaitheamh, léiríodh nach bhfuil baol ann go sárófaí an iontógáil laethúil inghlactha ná an ghéardháileog thagartha.
Neither the lifetime exposure to these substances via consumption of all food products that may contain them, nor the short-term exposure due to high consumption of the relevant products showed that there is a risk that the acceptable daily intake or the acute reference dose is exceeded.
Le teagmháil ar feadh an tsaoil leis an tsubstaint trí chaitheamh na dtáirgí bia go léir a bhféadfadh sí a bheith iontu, agus le teagmháil ghearrthéarmach trí go leor piseanna a bhfuil faighneoga orthu a chaitheamh, léiríodh nach bhfuil baol ann go sárófaí an iontógáil laethúil inghlactha nó an ghéardháileog thagartha.
Neither the lifetime exposure to the substance via consumption of all food products that may contain it, nor the short-term exposure due to high consumption of peas with pods showed that there is a risk that the acceptable daily intake or the acute reference dose is exceeded.
Léiríodh nach baol iad an teagmháil ar feadh an tsaoil leis na substaintí sin de bharr chaitheamh na dtáirgí bia a bhféadfaidís a bheith iontu, ná teagmháil ghearrthéarmach de bharr ráta ard caithimh na dtáirgí ábhartha, nach baol iad go sárófaí an iontógáil laethúil inghlactha, ná an ghéardháileog thagartha.
Neither the lifetime exposure to these substances via consumption of all food products that may contain them, nor the short-term exposure due to high consumption of the relevant products showed that there is a risk that the acceptable daily intake or the acute reference dose is exceeded.
Le teagmháil ar feadh an tsaoil leis na substaintí sin trí chaitheamh na dtáirgí bia go léir a bhféadfadh siad a bheith iontu, agus le teagmháil ghearrthéarmach trí go leor de na táirgí lena mbaineann a chaitheamh, léiríodh nach bhfuil baol ann go sárófaí an iontógáil laethúil inghlactha nó an ghéardháileog thagartha.
Neither the lifetime exposure to these substances via consumption of all food products that may contain them, nor the short-term exposure due to high consumption of the relevant products showed that there is a risk that the acceptable daily intake or the acute reference dose is exceeded.
Dheimhnigh an tÚdarás an ghéardháileog thagartha (ARfD) ina bhfuil 10 μg moirfín/kg de mheáchan coirp (bw) agus chinn sé gur cheart tiúchan an chóidín sna samplaí de shíolta poipín a chur san áireamh trí chóidín a thiontú ina gcoibhéisí moirfín, trí úsáid a bhaint as fachtóir 0,2.
The Authority confirmed the acute reference dose (ARfD) of 10 μg morphine/kg body weight (bw) and concluded that the concentration of codeine in the poppy seed samples should be taken into account by converting codeine to morphine equivalents, using a factor of 0,2.
Le teagmháil ar feadh an tsaoil leis an tsubstaint sin trí chaitheamh na dtáirgí bia go léir a bhféadfadh sí a bheith iontu, agus le teagmháil ghearrthéarmach trí go leor de na táirgí lena mbaineann a chaitheamh, léiríodh nach bhfuil baol ann go sárófaí an iontógáil laethúil inghlactha nó an ghéardháileog thagartha.
Neither the lifetime exposure to this substance via consumption of all food products that may contain it, nor the short-term exposure due to high consumption of the relevant products showed that there is a risk that the acceptable daily intake or the acute reference dose is exceeded.
Le teagmháil ar feadh an tsaoil leis na substaintí sin trí chaitheamh na dtáirgí bia go léir a bhféadfadh siad a bheith iontu, agus le teagmháil ghearrthéarmach trí go leor de na táirgí lena mbaineann a chaitheamh, léiríodh go bhfuil baol ann go sárófaí an iontógáil laethúil inghlactha nó an ghéardháileog thagartha.
Neither the lifetime exposure to these substances via consumption of all food products that may contain them, nor the short-term exposure due to high consumption of the relevant products showed a risk of exceeding the acceptable daily intake or the acute reference dose.
Léiríodh nach baol do dhuine an iontógáil laethúil inghlactha a shárú, ná an ghéardháileog thagartha a shárú, de bharr ceachtar den dá rud seo: teagmháil ar feadh a shaoil leis na substaintí sin trí chaitheamh na dtáirgí bia go léir a bhféadfaidís a bheith iontu, ná teagmháil ghearrthéarmach trí go leor de na táirgí lena mbaineann a chaitheamh.
Neither the lifetime exposure to these substances via consumption of all food products that may contain them, nor the short-term exposure due to high consumption of the relevant products showed that there is a risk that the acceptable daily intake or the acute reference dose is exceeded.
Léiríodh nach baol do dhuine an iontógáil laethúil inghlactha a shárú, ná an ghéardháileog thagartha a shárú, de bharr ceachtar den dá rud seo: teagmháil ar feadh a shaoil leis na substaintí sin trí chaitheamh na dtáirgí bia go léir a bhféadfaidís a bheith iontu, ná teagmháil ghearrthéarmach trí go leor de na táirgí lena mbaineann a chaitheamh.
Neither the lifetime exposure to these substances via consumption of all food products that may contain them, nor the short-term exposure due to high consumption of the relevant products showed that there is a risk that the acceptable daily intake or the acute reference dose is exceeded.
I gcás meatocsaifeinisíde, i gcomhthéacs an nós imeachta chun formheas na substainte gníomhaí sin a athnuachan i gcomhréir le Rialachán (CE) Uimh. 1107/2009 ó Pharlaimint na hEorpa agus ón gComhairle, d’fhoilsigh an tÚdarás Eorpach um Shábháilteacht Bia (“an tÚdarás”) conclúid maidir leis an athbhreithniú piaraí ar an measúnú riosca ar an tsubstaint ghníomhach sin, lena ndeimhnítear an iontógáil laethúil inghlactha (ILI) atá ann cheana agus lena mbunaítear géardháileog thagartha níos ísle (ARfD).
For methoxyfenozide, in the context of the procedure for the renewal of the approval of that active substance in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, the European Food Safety Authority (‘the Authority’) published a conclusion on the peer review of the risk assessment of that active substance, confirming the existing acceptable daily intake (ADI) and establishing a lower acute reference dose (ARfD).
Le teagmháil ar feadh an tsaoil leis an tsubstaint sin trí chaitheamh na dtáirgí bia go léir a bhféadfadh sí a bheith iontu, agus le teagmháil ghearrthéarmach trí go leor de na táirgí lena mbaineann a chaitheamh, léiríodh nach bhfuil baol ann go sárófaí an iontógáil laethúil inghlactha nó an ghéardháileog thagartha.
Neither the lifetime exposure to this substance via consumption of all food products that may contain it, nor the short-term exposure due to high consumption of the relevant products showed that there is a risk that the acceptable daily intake or the acute reference dose is exceeded.
Maidir le teagmháil fhadtéarmach leis na substaintí sin trí chaitheamh na dtáirgí bia go léir a bhféadfadh siad a bheith iontu, agus maidir le teagmháil ghearrthéarmach trí go leor de na táirgí lena mbaineann a chaitheamh, níor léiríodh baol i leith ceachtar acu sin go sárófaí an iontógáil laethúil inghlactha nó an ghéardháileog thagartha.
Neither the long-term exposure to these substances via consumption of all food products that may contain them, nor the short-term exposure due to high consumption of the relevant products showed a risk that the acceptable daily intake or the acute reference dose is exceeded.
Maidir le teagmháil fhadtéarmach leis an tsubstaint sin trí chaitheamh na dtáirgí bia go léir a bhféadfadh sí a bheith iontu, agus maidir le teagmháil ghearrthéarmach trí go leor den táirge lena mbaineann a chaitheamh, níor léiríodh baol i leith ceachtar acu sin go sáraítear an iontógáil laethúil inghlactha ná an ghéardháileog thagartha.
Neither the long-term exposure to this substance via consumption of all food products that may contain it, nor the short-term exposure due to high consumption of the relevant product showed a risk that the acceptable daily intake or the acute reference dose is exceeded.
Maidir le teagmháil ar feadh an tsaoil leis an tsubstaint trí chaitheamh na dtáirgí bia go léir a bhféadfadh sí a bheith iontu, agus maidir le teagmháil ghearrthéarmach trí go leor de na táirgí lena mbaineann a chaitheamh, níor léiríodh baol i leith ceachtar acu sin go sáraítear an iontógáil laethúil inghlactha nó an ghéardháileog thagartha.
Neither the lifetime exposure to the substance via consumption of all food products that may contain them, nor the short-term exposure due to high consumption of the relevant products showed that there is a risk that the acceptable daily intake or the acute reference dose is exceeded.
Maidir le teagmháil fhadtéarmach leis an tsubstaint sin trí chaitheamh na dtáirgí bia go léir a bhféadfadh sí a bheith iontu, agus maidir le teagmháil ghearrthéarmach trí go leor den táirge lena mbaineann a chaitheamh, níor léiríodh baol i leith ceachtar acu sin go sáraítear an iontógáil laethúil inghlactha ná an ghéardháileog thagartha.
Neither the long-term exposure to that substance via consumption of all food products that may contain it, nor the short-term exposure due to high consumption of the relevant products showed a risk that the acceptable daily intake or the acute reference dose is exceeded.
Maidir le teagmháil fhadtéarmach leis an tsubstaint sin trí chaitheamh na dtáirgí bia go léir a bhféadfadh sí a bheith iontu, agus maidir le teagmháil ghearrthéarmach trí go leor den táirge lena mbaineann a chaitheamh, níor léiríodh baol i leith ceachtar acu sin go sáraítear an iontógáil laethúil inghlactha ná an ghéardháileog thagartha.
Neither the long-term exposure to this substance via consumption of all food products that may contain it, nor the short-term exposure due to high consumption of the relevant products showed a risk that the acceptable daily intake or the acute reference dose is exceeded.
Maidir le flutríafól i nguird a bhfuil craiceann do-ite acu, is iomchuí an MRL a leagan síos ag an leibhéal a shainaithin an tÚdarás.
The Authority concluded that all requirements with respect to completeness of data submission were met and that the modification to the MRLs requested by the applicant was acceptable with regard to consumer safety on the basis of a consumer exposure assessment for 27 specific European consumer groups. In so concluding, the Authority took into account the most recent data on the toxicological properties of the substances. Neither the long-term exposure to the substance via consumption of all food products that may contain it, nor the short-term exposure due to high consumption of the relevant products showed a risk that the acceptable daily intake or the acute reference dose is exceeded.
Maidir le teagmháil fhadtéarmach leis na substaintí sin trí chaitheamh na dtáirgí bia go léir a bhféadfadh siad a bheith iontu, agus maidir le teagmháil ghearrthéarmach trí go leor de na táirgí lena mbaineann a chaitheamh, níor léiríodh baol i leith ceachtar acu sin go sárófaí an iontógáil laethúil inghlactha nó an ghéardháileog thagartha.
Neither the long-term exposure to these substances via consumption of all food products that may contain them, nor the short-term exposure due to high consumption of the relevant products showed a risk that the acceptable daily intake or the acute reference dose is exceeded.
Maidir le teagmháil fhadtéarmach leis an tsubstaint sin trí chaitheamh na dtáirgí bia go léir a bhféadfadh sí a bheith iontu, agus maidir le teagmháil ghearrthéarmach trí go leor den táirge lena mbaineann a chaitheamh, níor léiríodh baol i leith ceachtar acu sin go sáraítear an iontógáil laethúil inghlactha ná an ghéardháileog thagartha.
Neither the long-term exposure to this substance via consumption of all food products that may contain it, nor the short-term exposure due to high consumption of the relevant products showed a risk that the acceptable daily intake or the acute reference dose is exceeded.
Maidir le teagmháil fhadtéarmach leis na substaintí sin trí chaitheamh na dtáirgí bia go léir a bhféadfadh siad a bheith iontu, agus maidir le teagmháil ghearrthéarmach trí go leor de na táirgí lena mbaineann a chaitheamh, níor léiríodh baol i leith ceachtar acu sin go sárófaí an iontógáil laethúil inghlactha nó an ghéardháileog thagartha.
Neither the long-term exposure to these substances via consumption of all food products that may contain them, nor the short-term exposure due to high consumption of the relevant products showed a risk that the acceptable daily intake or the acute reference dose is exceeded.
Maidir le teagmháil fhadtéarmach leis an tsubstaint sin trí chaitheamh na dtáirgí bia go léir a bhféadfadh sí a bheith iontu, agus maidir le teagmháil ghearrthéarmach trí go leor den táirge lena mbaineann a chaitheamh, níor léiríodh baol i leith ceachtar acu sin go sáraítear an iontógáil laethúil inghlactha ná an ghéardháileog thagartha.
Neither the long-term exposure to this substance via consumption of all food products that may contain it, nor the short-term exposure due to high consumption of the relevant products showed a risk that the acceptable daily intake or the acute reference dose is exceeded.
Maidir le teagmháil fhadtéarmach leis na substaintí sin trí chaitheamh na dtáirgí bia go léir a bhféadfadh siad a bheith iontu, agus maidir le teagmháil ghearrthéarmach trí go leor de na táirgí lena mbaineann a chaitheamh, níor léiríodh baol i leith ceachtar acu sin go sárófaí an iontógáil laethúil inghlactha nó an ghéardháileog thagartha.
Neither the long-term exposure to these substances via consumption of all food products that may contain them, nor the short-term exposure due to high consumption of the relevant products showed a risk that the acceptable daily intake or the acute reference dose is exceeded.
I gcomhthéacs an nós imeachta chun formheas na substainte gníomhaí sin a athnuachan i gcomhréir le Rialachán (CE) Uimh. 1107/2009 ó Pharlaimint na hEorpa agus ón gComhairle, d’fhoilsigh an tÚdarás Eorpach um Shábháilteacht Bia (‘an tÚdarás’) conclúid maidir leis an athbhreithniú piaraí ar an measúnú riosca ar an tsubstaint ghníomhach sin, lena mbunaítear iontógáil laethúil inghlactha (ILI) níos ísle agus géardháileog thagartha níos ísle (ARfD).
In the context of the procedure for the renewal of the approval of that active substance in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, the European Food Safety Authority (‘the Authority’) published a conclusion on the peer review of the risk assessment of that active substance, establishing a lower acceptable daily intake (ADI) and a lower acute reference dose (ARfD).
Maidir le teagmháil fhadtéarmach leis na substaintí sin trí chaitheamh na dtáirgí bia go léir a bhféadfadh siad a bheith iontu, agus maidir le teagmháil ghearrthéarmach trí go leor de na táirgí lena mbaineann a chaitheamh, ní léirítear baol i leith ceachtar acu sin go sárófaí an iontógáil laethúil inghlactha nó an ghéardháileog thagartha.
Neither the long-term exposure to these substances via consumption of all food products that may contain them nor the short-term exposure due to high consumption of relevant products show a risk that the acceptable daily intake or the acute reference dose is exceeded.
Le teagmháil ar feadh an tsaoil leis an tsubstaint sin trí chaitheamh na dtáirgí bia go léir a bhféadfadh sí a bheith iontu, agus le teagmháil ghearrthéarmach trí go leor de na táirgí lena mbaineann a chaitheamh, léiríodh nach bhfuil baol ann go sárófaí an iontógáil laethúil inghlactha ná an ghéardháileog thagartha.
Neither the lifetime exposure to this substance via consumption of all food products that may contain it nor the short-term exposure due to high consumption of the relevant products show a risk that the acceptable daily intake or the acute reference dose is exceeded.
I gcomhthéacs an nós imeachta chun formheas na substainte gníomhaí iondocsacarb a athnuachan i gcomhréir le Rialachán (CE) Uimh. 1107/2009 ó Pharlaimint na hEorpa agus ón gComhairle, d’fhoilsigh an tÚdarás Eorpach um Shábháilteacht Bia (‘an tÚdarás’) conclúid maidir leis an athbhreithniú piaraí ar an measúnú riosca ar an tsubstaint ghníomhach sin, lena mbunaítear iontógáil laethúil inghlactha (‘ADI’) níos ísle agus géardháileog thagartha níos ísle (ARfD).
In the context of the procedure for the renewal of the approval of indoxacarb in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, the European Food Safety Authority (‘the Authority’) published a conclusion on the peer review of the risk assessment of that active substance, establishing a lower acceptable daily intake (‘ADI’) and a lower acute reference dose (‘ARfD’).
Tháinig an tÚdarás ar an gconclúid gur léiríodh nach bhfuil baol ann go sárófaí an iontógáil laethúil inghlactha nó an ghéardháileog thagartha le teagmháil ar feadh an tsaoil leis an tsubstaint sin trí chaitheamh na dtáirgí bia go léir a bhféadfadh sí a bheith iontu, ná le teagmháil ghearrthéarmach trí go leor de na táirgí lena mbaineann a chaitheamh, .
The Authority concluded that neither the lifetime exposure to the substance via consumption of all food products that may contain it, nor the short-term exposure due to high consumption of those products showed that there is any risk that the acceptable daily intake or the acute reference dose is exceeded.
Le teagmháil fhadtéarmach (ainsealach) leis an tsubstaint sin trí chaitheamh na dtáirgí bia go léir a bhféadfadh sí a bheith iontu, agus le teagmháil ghearrthéarmach(géar) trí go leor de na táirgí lena mbaineann a chaitheamh, léirítear nach bhfuil baol ann go sárófaí an iontógáil laethúil inghlactha nó an ghéardháileog thagartha.
Neither the long-term (chronic) exposure to that substance via consumption of all food products that may contain it nor the short-term (acute) exposure due to high consumption of relevant products show that there is any risk that the acceptable daily intake or the acute reference dose is exceeded.
Ar bhonn na tuairime réasúnaithe ón Údarás, agus na tosca ábhartha a liostaítear in Airteagal 14(2) de Rialachán (CE) Uimh. 396/2005 á gcur san áireamh, is iomchuí na MRLanna a mhodhnú faoi mar a leagtar amach san Iarscríbhinn a ghabhann leis an Rialachán seo.
The Authority concluded that all requirements with respect to completeness of data submission were met and proposed, based on the available data, setting a lower MRL that is acceptable with regard to consumer safety on the basis of a consumer exposure assessment for 27 specific European consumer groups. In so concluding, the Authority took into account the most recent data on the toxicological properties of the substances. Neither the long-term exposure to these substances via consumption of all food products that may contain them, nor the short-term exposure due to high consumption of the relevant products showed a risk that the acceptable daily intake or the acute reference dose is exceeded.